vs
Side-by-side financial comparison of HACKETT GROUP, INC. (HCKT) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.
HACKETT GROUP, INC. is the larger business by last-quarter revenue ($68.8M vs $37.2M, roughly 1.8× Organogenesis Holdings Inc.). On growth, HACKETT GROUP, INC. posted the faster year-over-year revenue change (-11.6% vs -57.1%). Over the past eight quarters, HACKETT GROUP, INC.'s revenue compounded faster (-5.9% CAGR vs -46.5%).
Hackett Limited is a British multi-channel retailer of clothing for men and boys, with a broad range of apparel and accessories. It was founded in 1983 in London, England. As of June 2019, the company had 160 stores globally, with its flagship store at 14 Savile Row in London. It is owned by both Lebanese holding company M1 Group and American L Capital Asia
Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.
HCKT vs ORGO — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $68.8M | $37.2M |
| Net Profit | $4.3M | — |
| Gross Margin | 70.8% | 30.8% |
| Operating Margin | 13.0% | -185.1% |
| Net Margin | 6.2% | — |
| Revenue YoY | -11.6% | -57.1% |
| Net Profit YoY | 36.2% | — |
| EPS (diluted) | $0.17 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $68.8M | $37.2M | ||
| Q4 25 | $75.8M | $225.6M | ||
| Q3 25 | $73.1M | $150.9M | ||
| Q2 25 | $78.9M | $101.0M | ||
| Q1 25 | $77.9M | $86.7M | ||
| Q4 24 | $79.2M | $126.7M | ||
| Q3 24 | $79.8M | $115.2M | ||
| Q2 24 | $77.7M | $130.2M |
| Q1 26 | $4.3M | — | ||
| Q4 25 | $5.6M | $43.7M | ||
| Q3 25 | $2.5M | $21.6M | ||
| Q2 25 | $1.7M | $-9.4M | ||
| Q1 25 | $3.1M | $-18.8M | ||
| Q4 24 | $3.6M | $7.7M | ||
| Q3 24 | $8.6M | $12.3M | ||
| Q2 24 | $8.7M | $-17.0M |
| Q1 26 | 70.8% | 30.8% | ||
| Q4 25 | 41.7% | — | ||
| Q3 25 | 40.7% | — | ||
| Q2 25 | 35.4% | — | ||
| Q1 25 | 35.8% | 72.6% | ||
| Q4 24 | 39.4% | 75.5% | ||
| Q3 24 | 29.2% | 76.7% | ||
| Q2 24 | 27.5% | 77.6% |
| Q1 26 | 13.0% | -185.1% | ||
| Q4 25 | 12.0% | 28.1% | ||
| Q3 25 | 7.5% | 13.7% | ||
| Q2 25 | 5.8% | -12.5% | ||
| Q1 25 | 5.7% | -30.9% | ||
| Q4 24 | 9.8% | 8.1% | ||
| Q3 24 | 16.0% | 5.4% | ||
| Q2 24 | 16.1% | -10.7% |
| Q1 26 | 6.2% | — | ||
| Q4 25 | 7.4% | 19.4% | ||
| Q3 25 | 3.5% | 14.3% | ||
| Q2 25 | 2.1% | -9.3% | ||
| Q1 25 | 4.0% | -21.7% | ||
| Q4 24 | 4.5% | 6.1% | ||
| Q3 24 | 10.8% | 10.7% | ||
| Q2 24 | 11.3% | -13.1% |
| Q1 26 | $0.17 | — | ||
| Q4 25 | $0.20 | $0.31 | ||
| Q3 25 | $0.09 | $0.11 | ||
| Q2 25 | $0.06 | $-0.10 | ||
| Q1 25 | $0.11 | $-0.17 | ||
| Q4 24 | $0.11 | $0.05 | ||
| Q3 24 | $0.31 | $0.09 | ||
| Q2 24 | $0.31 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $91.4M |
| Total DebtLower is stronger | $78.8M | — |
| Stockholders' EquityBook value | $66.0M | — |
| Total Assets | $204.4M | $520.0M |
| Debt / EquityLower = less leverage | 1.19× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $91.4M | ||
| Q4 25 | $18.2M | $93.7M | ||
| Q3 25 | $13.9M | $63.7M | ||
| Q2 25 | $10.1M | $73.1M | ||
| Q1 25 | $9.2M | $110.0M | ||
| Q4 24 | $16.4M | $135.6M | ||
| Q3 24 | $10.0M | $94.3M | ||
| Q2 24 | $19.1M | $89.9M |
| Q1 26 | $78.8M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $62.3M | ||
| Q2 24 | — | $63.8M |
| Q1 26 | $66.0M | — | ||
| Q4 25 | $68.1M | $300.1M | ||
| Q3 25 | $101.6M | $255.1M | ||
| Q2 25 | $119.8M | $233.2M | ||
| Q1 25 | $114.4M | $242.9M | ||
| Q4 24 | $115.6M | $262.9M | ||
| Q3 24 | $110.9M | $278.5M | ||
| Q2 24 | $102.2M | $263.5M |
| Q1 26 | $204.4M | $520.0M | ||
| Q4 25 | $206.4M | $598.7M | ||
| Q3 25 | $200.7M | $509.8M | ||
| Q2 25 | $200.5M | $461.1M | ||
| Q1 25 | $191.8M | $467.4M | ||
| Q4 24 | $193.3M | $497.9M | ||
| Q3 24 | $190.8M | $446.3M | ||
| Q2 24 | $187.5M | $443.2M |
| Q1 26 | 1.19× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.22× | ||
| Q2 24 | — | 0.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HCKT
| Revenue before reimbursements | $36.4M | 53% |
| Other | $32.0M | 47% |
| Reimbursements | $405.0K | 1% |
ORGO
Segment breakdown not available.
